Glucagon

Identification

Name
Glucagon
Accession Number
DB00040 / 76LA80IG2G
Groups
Glucag0n
Description

Glucagon is a 29 residue peptide hormone. Glucagon is synthesized in a unique non-pathogenic laboratory strain of Escherichia coli micro organism that has been genetically altered by the addition of the gene for glucagons.

Pharmacology

Pharmacodynamics

Used in the treatment of hypoglycemia and in gastric imaging, glucagon increases blood glucose concentration and is used in the treatment of hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose through the release of insulin. It also relaxes the smooth muscles of the gastrointestinal tract.

Indication

For treatment of severe hypoglycemia, also used in gastrointestinal imaging

Action

Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers. This yields glucose molecules to be released into the blood. Glucagon receptors are found in the liver, kidney, brain and pancreatic islet cells. The glucagon mediated signals lead to an increase in insulin excretion